191 related articles for article (PubMed ID: 6692363)
1. Determinants of intrinsic sensitivity to Vinca alkaloids in xenografts of pediatric rhabdomyosarcomas.
Houghton JA; Williams LG; Torrance PM; Houghton PJ
Cancer Res; 1984 Feb; 44(2):582-90. PubMed ID: 6692363
[TBL] [Abstract][Full Text] [Related]
2. Relationship between binding affinity, retention and sensitivity of human rhabdomyosarcoma xenografts to Vinca alkaloids.
Houghton JA; Williams LG; Dodge RK; George SL; Hazelton BJ; Houghton PJ
Biochem Pharmacol; 1987 Jan; 36(1):81-8. PubMed ID: 3541941
[TBL] [Abstract][Full Text] [Related]
3. Stability of vincristine complexes in cytosols derived from xenografts of human rhabdomyosarcoma and normal tissues of the mouse.
Houghton JA; Williams LG; Houghton PJ
Cancer Res; 1985 Aug; 45(8):3761-7. PubMed ID: 2990677
[TBL] [Abstract][Full Text] [Related]
4. In situ selection of a human rhabdomyosarcoma resistant to vincristine with altered beta-tubulins.
Houghton JA; Houghton PJ; Hazelton BJ; Douglass EC
Cancer Res; 1985 Jun; 45(6):2706-12. PubMed ID: 3986804
[TBL] [Abstract][Full Text] [Related]
5. Reciprocal cross-resistance in human rhabdomyosarcomas selected in vivo for primary resistance to vincristine and L-phenylalanine mustard.
Horton JK; Houghton PJ; Houghton JA
Cancer Res; 1987 Dec; 47(23):6288-93. PubMed ID: 2890432
[TBL] [Abstract][Full Text] [Related]
6. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.
Thompson J; George EO; Poquette CA; Cheshire PJ; Richmond LB; de Graaf SS; Ma M; Stewart CF; Houghton PJ
Clin Cancer Res; 1999 Nov; 5(11):3617-31. PubMed ID: 10589779
[TBL] [Abstract][Full Text] [Related]
7. Studies with 4'-deoxyepivincristine (vinepidine), a semisynthetic vinca alkaloid.
Mullin K; Houghton PJ; Houghton JA; Horowitz ME
Biochem Pharmacol; 1985 Jun; 34(11):1975-9. PubMed ID: 4004913
[TBL] [Abstract][Full Text] [Related]
8. Use of snail neurons in developing quantitative ultrastructural parameters for neurotoxic side effects of Vinca antitumor agents.
Müller LJ; Moorer-van Delft CM; Zijl R; Roubos EW
Cancer Res; 1990 Mar; 50(6):1924-8. PubMed ID: 2407348
[TBL] [Abstract][Full Text] [Related]
9. Factors governing the modulation of vinca-alkaloid resistance in doxorubicin-resistant cells by the calmodulin inhibitor trifluoperazine.
Ganapathi R; Grabowski D; Schmidt H
Biochem Pharmacol; 1986 Feb; 35(4):673-8. PubMed ID: 3947398
[TBL] [Abstract][Full Text] [Related]
10. Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts.
Horton JK; Thimmaiah KN; Houghton JA; Horowitz ME; Houghton PJ
Biochem Pharmacol; 1989 Jun; 38(11):1727-36. PubMed ID: 2735930
[TBL] [Abstract][Full Text] [Related]
11. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
[TBL] [Abstract][Full Text] [Related]
12. Accumulation and release of vinblastine and vincristine by HeLa cells: light microscopic, cinematographic, and biochemical study.
Lengsfeld AM; Dietrich J; Schultze-Maurer B
Cancer Res; 1982 Sep; 42(9):3798-805. PubMed ID: 7105045
[TBL] [Abstract][Full Text] [Related]
13. Response of cultured human cell lines from rhabdomyosarcoma xenografts to treatment with chloroethylnitrosoureas.
Smith DG; Brent TP
Cancer Res; 1989 Feb; 49(4):883-6. PubMed ID: 2521455
[TBL] [Abstract][Full Text] [Related]
14. The distribution of [3H]vinblastine in tumor and host tissues of Nb rats bearting a transplantable lymphoma which is highly sensitive to the alkaloid.
Noble RL; Gout PW; Wijcik LL; Hebden HF; Beer CT
Cancer Res; 1977 May; 37(5):1455-60. PubMed ID: 856464
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
16. Energy-dependent reduced drug binding as a mechanism of Vinca alkaloid resistance in human leukemic lymphoblasts.
Beck WT; Cirtain MC; Lefko JL
Mol Pharmacol; 1983 Nov; 24(3):485-92. PubMed ID: 6579344
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion.
Rosenberg MC; Colvin OM; Griffith OW; Bigner SH; Elion GB; Horton JK; Lilley E; Bigner DD; Friedman HS
Cancer Res; 1989 Dec; 49(24 Pt 1):6917-22. PubMed ID: 2582434
[TBL] [Abstract][Full Text] [Related]
18. Scheduling of vincristine: drug accumulation and response of xenografts of childhood rhabdomyosarcoma determined by frequency of administration.
Houghton JA; Meyer WH; Houghton PJ
Cancer Treat Rep; 1987; 71(7-8):717-21. PubMed ID: 3607783
[TBL] [Abstract][Full Text] [Related]
19. Reversal of Vinca alkaloid resistance by anti-P-glycoprotein monoclonal antibody HYB-241 in a human tumor xenograft.
Rittmann-Grauer LS; Yong MA; Sanders V; Mackensen DG
Cancer Res; 1992 Apr; 52(7):1810-6. PubMed ID: 1348013
[TBL] [Abstract][Full Text] [Related]
20. Relationship between the cellular accumulation and the cytotoxicity of S12363, a new Vinca alkaloid derivative.
Pierré A; Pérez V; Léonce S; Boutin JA; Saint-Dizier D; Hautefaye P; Lavielle G; Atassi G
Cancer Chemother Pharmacol; 1992; 29(5):367-74. PubMed ID: 1551175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
